NO20054721L - Substituerte anilinderivater - Google Patents

Substituerte anilinderivater

Info

Publication number
NO20054721L
NO20054721L NO20054721A NO20054721A NO20054721L NO 20054721 L NO20054721 L NO 20054721L NO 20054721 A NO20054721 A NO 20054721A NO 20054721 A NO20054721 A NO 20054721A NO 20054721 L NO20054721 L NO 20054721L
Authority
NO
Norway
Prior art keywords
aniline derivatives
substituted aniline
derivatives
pharmaceutically acceptable
general formula
Prior art date
Application number
NO20054721A
Other languages
English (en)
Norwegian (no)
Inventor
Mario Rottlander
Daniel Rodriguez Greve
William Patrick Watson
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2004/000162 external-priority patent/WO2004080950A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20054721L publication Critical patent/NO20054721L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20054721A 2003-03-14 2005-10-13 Substituerte anilinderivater NO20054721L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300392 2003-03-14
PCT/DK2004/000162 WO2004080950A1 (en) 2003-03-14 2004-03-12 Substituted aniline derivatives

Publications (1)

Publication Number Publication Date
NO20054721L true NO20054721L (no) 2005-10-13

Family

ID=58707220

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054721A NO20054721L (no) 2003-03-14 2005-10-13 Substituerte anilinderivater

Country Status (12)

Country Link
US (1) US20060167087A1 (ko)
KR (1) KR20050117563A (ko)
CN (1) CN1759099A (ko)
AR (1) AR043507A1 (ko)
CL (1) CL2004000488A1 (ko)
EA (1) EA200501299A1 (ko)
IS (1) IS7924A (ko)
NO (1) NO20054721L (ko)
NZ (1) NZ541242A (ko)
SG (1) SG171472A1 (ko)
UA (1) UA81799C2 (ko)
ZA (1) ZA200505357B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
JP2011525538A (ja) * 2008-06-24 2011-09-22 バレアント プハルマセウトイカルス インターナショナル カリウムチャネルモジュレーターとして有用なベンジルオキシアニリド誘導体
US20130108687A1 (en) 2010-05-21 2013-05-02 Universitat Fur Bodenkultur Wien Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
US20130210883A1 (en) 2010-05-21 2013-08-15 Johannes Grillari Lipase inhibitors
WO2014114649A1 (en) * 2013-01-22 2014-07-31 Technische Universität Graz Lipase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3903989A1 (de) * 1989-02-10 1990-09-20 Basf Ag Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
CA2076012A1 (en) * 1990-02-14 1991-08-15 Yasuyuki Kato Agent for inhibiting the formation of denatured ldl
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
EP1369420A1 (en) * 2002-06-06 2003-12-10 Aventis Pharma Deutschland GmbH Inhibitors of the GPib - vWF interaction

Also Published As

Publication number Publication date
AR043507A1 (es) 2005-08-03
CN1759099A (zh) 2006-04-12
ZA200505357B (en) 2006-12-27
CL2004000488A1 (es) 2005-01-07
IS7924A (is) 2005-06-30
EA200501299A1 (ru) 2006-02-24
NZ541242A (en) 2009-01-31
SG171472A1 (en) 2011-06-29
US20060167087A1 (en) 2006-07-27
KR20050117563A (ko) 2005-12-14
UA81799C2 (uk) 2008-02-11

Similar Documents

Publication Publication Date Title
NO20054848L (no) Substituerte p-diaminobenzenderivater
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
NO20055562L (no) Substituerte indolin- og indolderivater
NO20071843L (no) Substituerte anilinderivater
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20073465L (no) Benzotiazol-derivater
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
NO20054721L (no) Substituerte anilinderivater
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20076648L (no) Novel thiophene derivatives
NO20081844L (no) Terapeutiske forbindelser
NO20071593L (no) Pyrimidinderivater
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application